TLR3 and neoplasm: Wang and co-workers developed a vaccine strategy by using the mPEG-b-PLVal hydrogel as the scaffold to encapsulate tumor cell lysates (TCLs) and a toll-like receptor 3 (TLR3) agonist, polyinosinic:polycytidylic acid (poly(I:C)) [26].